Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT01943838
- Locations
- 🇧🇪
Investigational Site Number 056001, Leuven, Belgium
Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2015-08-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 294
- Registration Number
- NCT01940965
- Locations
- 🇯🇵
Investigational Site Number 392328, Chiyoda-Ku, Japan
🇯🇵Investigational Site Number 392335, Adachi-Ku, Japan
🇯🇵Investigational Site Number 392310, Chuoh-Ku, Japan
A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies
- Conditions
- Neoplasm Malignant
- Interventions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT01930552
- Locations
- 🇨🇳
Investigational Site Number 156002, Beijing, China
🇨🇳Investigational Site Number 156001, Guangzhou, China
An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
- Conditions
- Nasal Polyps
- Interventions
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT01920893
- Locations
- 🇺🇸
Investigational Site Number 840013, Boston, Massachusetts, United States
🇺🇸Investigational Site Number 840014, Rolling Hills Estates, California, United States
🇺🇸Investigational Site Number 840015, Denver, Colorado, United States
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 58
- Registration Number
- NCT01907685
Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis
- Conditions
- Uveitis
- Interventions
- Drug: Folic/folinic acidOther: Placebo (for Sarilumab)
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 58
- Registration Number
- NCT01900431
- Locations
- 🇺🇸
Investigational Site Number 840007, Cleveland, Ohio, United States
🇹🇷Investigational Site Number 792004, Izmir, Turkey
🇹🇷Investigational Site Number 792006, Izmir, Turkey
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1001
- Registration Number
- NCT01895335
- Locations
- 🇺🇸
Investigational Site Number 840003, Canton, Ohio, United States
🇺🇸Investigational Site Number 840037, Fullerton, California, United States
🇺🇸Investigational Site Number 840104, Hialeah, Florida, United States
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2013-06-20
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 62
- Registration Number
- NCT01882868
- Locations
- 🇯🇵
Investigational Site Number 392002, Sunto-Gun, Japan
🇯🇵Investigational Site Number 392005, Suita-Shi, Japan
🇯🇵Investigational Site Number 392017, Fukuoka-Shi, Japan
Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 70
- Registration Number
- NCT01863888
- Locations
- 🇧🇪
Investigational Site Number 056003, Sijsele-Damme, Belgium
🇧🇪Investigational Site Number 056002, Overpelt, Belgium
🇩🇪Investigational Site Number 276-002, Ulm, Germany
Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 6
- Registration Number
- NCT01861249
- Locations
- 🇺🇸
Investigational Site Number 840008, Miramar,, Florida, United States
🇺🇸Investigational Site Number 840048, Winter Park, Florida, United States
🇺🇸Investigational Site Number 840088, San Antonio, Texas, United States